Other Conflicts:

April 9, 2007: Plans for Anemia Drug Run into Roadblocks: Hospital, Firm Eyed $12b Market
With an eye toward the anti-anemia drug market, BIDMC wasted resources by entering into a business relationship with a financially failing Florida drug company. Facing regulatory and safety concerns, the drug was never developed.  

Letter to BIDMC board regarding clinical trials and business venture with dealmaker tied to massive FDA fraud case
1199SEIU presented evidence that Beth Israel Deaconess Medical Center entered into a for-profit business venture with a figure who had a previous conviction for “shipment of adulterated devices,” including to the BIDMC itself. His prior conviction had led to what was, at the time, the largest fine ever imposed in an FDA fraud case. Still, BIDMC moved forward with the businessman to launch SomRx, a corporation formed to develop medical devices to treat sleep disorders. The company was inexplicably dissolved in 2007. Incentives to BIDMC insiders and testing of the device at the hospital raise issues around apparent conflicts of interest and oversight safeguards.